药明海德与羽冠生物达成战略合作 加速创新OMV疫苗技术全球应用

Core Insights - WuXi Biologics has entered a strategic partnership with Yuguan Biotech to advance the global application of innovative bacterial vaccine technologies [1][2] - The collaboration aims to leverage WuXi Biologics' integrated R&D and manufacturing capabilities in the vaccine CDMO sector, enhancing the development of Yuguan's OMV Plus platform [1] - The engineering of OMV vaccines has achieved GMP-scale production, with a fermentation yield exceeding 1 million doses per batch and production costs below $1 per dose [1] Group 1 - The partnership will contribute to the innovation of bacterial vaccines and support global public health initiatives [1] - The OMV Plus platform addresses technical challenges in bacterial vaccine antigen diversity and enhances protective efficacy without additional adjuvants [1] - Yuguan Biotech's technology has significantly improved OMV yield and broad-spectrum capabilities, facilitating the development of vaccines for nearly all Gram-negative bacteria [1] Group 2 - Dr. Lin Qiubin, CEO of Yuguan Biotech, expressed enthusiasm for the deepened collaboration, highlighting the successful scale-up of China's first B group meningococcal OMV vaccine [2] - The partnership has demonstrated the strength of Yuguan's vaccine innovation, achieving significant production cost reductions and increased output [2] - The collaboration is positioned to enhance the accessibility of innovative bacterial vaccines globally [2]